Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Jesse Bane

Internal Medicine West Valley City, UT Medical Doctor

NPI 1477584837 CMS profile 112169

3725 W 4100 South, West Valley City, UT 84120

Open in the dashboard

General payments

$2,076

147 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Jesse Bane of West Valley City, UT is reported in the CMS Open Payments database as having received $2,076 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $251 16
2019 General $1,825 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Bane
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jesse Bane were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jesse Bane Internal Medicine median Middle half National median
2019 $1,825 $159 $48–$570 $163
2020 $251 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Amgen Inc. $367 18 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $282 17 payments
  3. Pfizer Inc. $229 24 payments
  4. Janssen Pharmaceuticals, Inc $215 14 payments
  5. Sanofi-Aventis U.S. LLC $117 10 payments
  6. E.R. Squibb & Sons, L.L.C. $112 8 payments
  7. Astellas Pharma US Inc $92 6 payments
  8. Novo Nordisk Inc $91 7 payments
  9. Actelion Pharmaceuticals US, Inc. $76 7 payments
  10. GlaxoSmithKline, LLC. $71 5 payments
  11. Other $424 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $2,076 147 payments
Products named General payments · program years 2019–2020
  1. Repatha $331 15 payments
  2. INVOKANA $215 14 payments
  3. XARELTO $200 12 payments
  4. JARDIANCE $123 7 payments
  5. ELIQUIS Cardiovascular $112 8 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $109 8 payments
  7. COLOGUARD $97 13 payments
  8. SPIRIVA RESPIMAT $96 6 payments
  9. MYRBETRIQ $92 6 payments
  10. LYRICA $80 7 payments
  11. Other $1,673 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record